TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Trump Buys SpaceX Shares After Record IPO 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Add as a preferred source on Google
EDEN PRAIRIE, Minn., May 01, 2018 -- CHF Solutions, Inc. (Nasdaq:CHFS) announces today that its first quarter financial results will be released on Tuesday, May 8, 2018. The company will host a conference call and webcast at 9:00 AM ET that morning, during which management will discuss the company's financial results and provide a general business overview.
To access the live webcast, please visit the CHF Solutions website at http://ir.chf-solutions.com or access the webcast directly at https://edge.media-server.com/m6/p/dxgvnn8x. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID 8694787. An audio archive of the webcast and the call script will be available following the call on the Investor page at www.chf-solutions.com.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
[email protected]
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
[email protected]
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
[email protected]
